Treatment of childhood acute myeloid leukemia

Keyphrases

• Activating mutation 50%
• Acute Myeloid Leukemia 100%
• Acute Promyelocytic Leukemia 50%
• Age Groups 50%
• Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT) 50%
• Anticancer Agents 50%
• Biologic Features 50%
• Childhood Acute Lymphoblastic Leukemia 100%
• Children with Down Syndrome 50%
• CNS Prophylaxis 50%
• Cranial Irradiation 50%
• Current Treatment 50%
• High-risk Population 50%
• Intensive Chemotherapy 50%
• Late Effects 50%
• Late Effects of Cancer Treatment 50%
• Life Effects 50%
• Maintenance Treatment 50%
• Malignancy 50%
• Mechanism of Action 50%
• Minimal Residual Disease 50%
• Novel Agents 50%
• Pediatric Leukemia 100%
• Prognostic Factors 50%
• Prophylaxis Treatment 50%
• Quality of Life 50%
• Reasonable Doubt 50%
• Receptor Tyrosine Kinase 50%
• Stem Cell Transplantation 50%
• Supportive Care 50%
• Survival Rate 50%
• Tailored Therapy 50%
• Tailored Treatment 50%
• Targeted Therapy 100%
• Treatment Monitoring 50%
• Treatment Strategy 50%
• Treatment Therapy 50%
• Young children 50%

Medicine and Dentistry

• Acute Myeloid Leukemia 100%
• Acute Promyelocytic Leukemia 25%
• Adolescence 50%
• Allogeneic Stem Cell Transplantation 25%
• Anticarcinogen 25%
• Biological Product 25%
• Cancer 25%
• Chemotherapy 25%
• Diagnosis 25%
• Disease 25%
• Down Syndrome 25%
• High Risk Population 50%
• Late Effect 25%
• Late Effect of Treatment 25%
• Leukemia in Children 25%
• Maintenance Therapy 25%
• Minimal Residual Disease 25%
• Patient Monitoring 25%
• Pediatric Acute Myeloid Leukemia 50%
• Prognostic Factor 25%
• Protein Tyrosine Kinase 25%
• Quality of Life 25%
• Skull Irradiation 25%
• Stem Cell Therapy 25%
• Supportive Care 25%
• Survival Rate 25%
• Targeted Therapy 50%
• Toddlers 25%